Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(4.72)
# 754
Out of 4,662 analysts
535
Total ratings
49.5%
Success rate
14%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANVS Annovis Bio | Reiterated: Buy | $17 | $1.80 | +844.44% | 12 | Aug 19, 2026 | |
| HELP Cybin | Reiterated: Buy | $42 | $11.67 | +259.90% | 26 | Aug 17, 2026 | |
| DFTX Definium Therapeutics | Maintained: Buy | $58 → $64 | $46.18 | +38.59% | 19 | Aug 13, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $20 | $13.90 | +43.88% | 26 | Aug 13, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintained: Buy | $36 | $30.18 | +19.28% | 54 | Aug 12, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $27 → $18 | $2.61 | +589.66% | 21 | Aug 12, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $12 | $3.30 | +263.64% | 41 | Aug 12, 2026 | |
| STOK Stoke Therapeutics | Reiterated: Buy | $58 | $32.14 | +80.46% | 18 | Aug 12, 2026 | |
| ZVRA Zevra Therapeutics | Reiterated: Buy | $20 | $11.57 | +72.86% | 20 | Aug 11, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $21 | $13.57 | +54.75% | 5 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $29.74 | +31.16% | 18 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $210 | $154.23 | +36.16% | 42 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $245 → $248 | $212.55 | +16.68% | 84 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $24 | $11.82 | +103.05% | 3 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $8 | $7.29 | +9.74% | 23 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $4.09 | +1,122.49% | 12 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $0.7921 | +2,172.44% | 55 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $120 → $36 | $1.90 | n/a | 10 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $75 → $12 | $32.91 | n/a | 12 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $31.48 | n/a | 4 | Apr 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $36.58 | n/a | 9 | Jan 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 → $53 | $16.17 | n/a | 8 | Nov 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $35 → $19 | $18.19 | n/a | 4 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $109 | $12.97 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $194.21 | $9.65 | n/a | 7 | Dec 18, 2015 |
Annovis Bio
Aug 19, 2026
Reiterated: Buy
Price Target: $17
Current: $1.80
Upside: +844.44%
Cybin
Aug 17, 2026
Reiterated: Buy
Price Target: $42
Current: $11.67
Upside: +259.90%
Definium Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $58 → $64
Current: $46.18
Upside: +38.59%
COMPASS Pathways
Aug 13, 2026
Reiterated: Buy
Price Target: $20
Current: $13.90
Upside: +43.88%
ACADIA Pharmaceuticals
Aug 12, 2026
Maintained: Buy
Price Target: $36
Current: $30.18
Upside: +19.28%
CervoMed
Aug 12, 2026
Reiterated: Buy
Price Target: $27 → $18
Current: $2.61
Upside: +589.66%
Voyager Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $12
Current: $3.30
Upside: +263.64%
Stoke Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $58
Current: $32.14
Upside: +80.46%
Zevra Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $20
Current: $11.57
Upside: +72.86%
Biohaven
Aug 11, 2026
Reiterated: Buy
Price Target: $21
Current: $13.57
Upside: +54.75%
Aug 6, 2026
Maintained: Buy
Price Target: $39
Current: $29.74
Upside: +31.16%
Aug 3, 2026
Reiterated: Buy
Price Target: $200 → $210
Current: $154.23
Upside: +36.16%
Jul 30, 2026
Reiterated: Buy
Price Target: $245 → $248
Current: $212.55
Upside: +16.68%
Jul 27, 2026
Maintained: Buy
Price Target: $35 → $24
Current: $11.82
Upside: +103.05%
Jul 17, 2026
Reiterated: Buy
Price Target: $17 → $8
Current: $7.29
Upside: +9.74%
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $4.09
Upside: +1,122.49%
Sep 5, 2025
Reiterated: Buy
Price Target: $18
Current: $0.7921
Upside: +2,172.44%
Jun 12, 2024
Downgraded: Hold
Price Target: $120 → $36
Current: $1.90
Upside: n/a
Jan 28, 2022
Downgraded: Hold
Price Target: $75 → $12
Current: $32.91
Upside: n/a
Apr 9, 2018
Maintained: Hold
Price Target: n/a
Current: $31.48
Upside: n/a
Jan 31, 2017
Upgraded: Buy
Price Target: n/a
Current: $36.58
Upside: n/a
Nov 9, 2016
Reiterated: Buy
Price Target: $66 → $53
Current: $16.17
Upside: n/a
Nov 7, 2016
Reiterated: Sell
Price Target: $35 → $19
Current: $18.19
Upside: n/a
Jun 14, 2016
Reiterated: Sell
Price Target: $109
Current: $12.97
Upside: n/a
Dec 18, 2015
Maintained: Buy
Price Target: $194.21
Current: $9.65
Upside: n/a